Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Randomized Controlled First in Human Trial to Assess the Feasibility and Preliminary Safety Data of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill PatientS with Sepsis-induced ImmunOsuppREssion (RESTORE I)

NCT06258291 is registered in ClinicalTrials.gov with hemotune AG as lead sponsor.

NCT NCT06258291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06258291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Randomized Controlled First in Human Trial to Assess the Feasibility and Preliminary Safety Data of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill PatientS with Sepsis-induced ImmunOsuppREssion (RESTORE I)
Lead sponsor
hemotune AG
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 30, 2026
Enrollment
16 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock